Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2378-2385

  Lin, Chih Wei ^a   Chang, Ching Yun ^a   Chen, Wei Lin ^a   Lin, Shih Chang ^a   Liao, Chien Chun ^a   Chang, Jui Yuan ^a   Liu, Chia Chyi ^a   Hu, Alan Yung Chih ^a   Lu, Tsung Chun ^a   Chou, Ai Hsiang ^a   Wu, Suh Chin ^b   Chong, Pele ^a,b,c   Huang, Ming Hsi ^a  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Adjuvant; Combination vaccine; Enterovirus 71; Influenza; Japanese encephalitis

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; ENTEROVIRUS INFLUENZA JAPANESE ENCEPHALITIS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VACCINE; ALUMINUM POTASSIUM SULFATE; ALUMINUM SULFATE; EMULSION; IMMUNOLOGICAL ADJUVANT; VACCINE; VIRUS ANTIBODY;

ARTICLE; CELLULAR IMMUNITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG FORMULATION; DRUG SYNTHESIS; EMULSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL MONITORING; VIRION; VIRUS PARTICLE; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; ENTEROVIRUS; IMMUNOLOGY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; JAPANESE ENCEPHALITIS VIRUS;

ADJUVANTS, IMMUNOLOGIC; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; DRUG COMPOUNDING; EMULSIONS; ENCEPHALITIS VIRUS, JAPANESE; ENTEROVIRUS A, HUMAN; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; MICE, INBRED BALB C; VACCINES, COMBINED; VIRAL VACCINES; VIRION;

EID: 84887469706     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25639     Document Type: Article

References (23)

1. National Center for Immunization and Respiratory Diseases. General recommendations on immunization - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60: 1-64; PMID: 21293327
2. Centers for Disease Control and Prevention. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR Recomm Rep 1999; 48: 1-15
3. Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years-United States 2012. MMWR QuickGuide 2012; 61: 1-4
4. American Academy of Pediatrics. Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). Pediatrics 1999; 103: 1064-77; PMID: 10224194; http://dx.doi.org/10.1542/peds.103.5.1064
5. Spier RE. Multivalent vaccines: prospects and challenges. Folia Microbiol (Praha) 1997; 42: 105-12; PMID: 9306653; http://dx.doi.org/10.1007/BF02898716 (Pubitemid 127443110)
6. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol 2006; 27: 573-9; PMID: 17049307; http://dx.doi.org/10.1016/j.it.2006.10.005 (Pubitemid 44708833)
7. Hubbell JA, Thomas SN, Swartz MA. Materials engineering for immunomodulation. Nature 2009; 462: 449-60; PMID: 19940915; http://dx.doi.org/ 10.1038/nature08604
8. O'Hagan DT, De Gregorio E. The path to a successful vaccine adjuvant-'the long and winding road'. Drug D i s c o v To d a y 2009; 14: 541-51; PMID: 19508916; http://dx.doi.org/10.1016/j.drudis.2009.02.009
9. World Health Organization. WHO recommendations on pandemic (H1N1) 2009 vaccines. Geneva: Pandemic (H1N1) briefing note 2. Accessed 2009 Jul 13. Available: http://www.who.int/csr/disease/swineflu/notes/h1n1-vaccine-20090713/ en/.
10. Huang MH, Huang CY, Lin SC, Chen JH, Ku CC, Chou AH, et al. Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes Infect 2009; 11: 654-60; PMID: 1934 4782; http://dx.doi.org/10.1016/j.micinf.2009.03.003
11. Huang MH, Lin SC, Hsiao CH, Chao HJ, Yang HR, Liao CC, et al. Emulsified nanoparticles containing inactivated influenza virus and CpG oligodeoxynucleotides critically influences the host immune responses in mice. PLoS One 2010; 5:e12279; PMID: 20808862; http://dx.doi.org/10.1371/journal.pone. 0012279
12. Weeratna RD, McCluskie MJ, Xu Y, Davis HL. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000; 18: 1755-62; PMID: 10699323; http://dx.doi.org/10.1016/S0264-410X(99)00526-5 (Pubitemid 30122837)
13. Liu CC, Guo MS, Lin FHY, Hsiao KN, Chang KHW, Chou AH, et al. Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system. PLoS One 2011; 6:e20005; PMID: 21603631; http://dx.doi.org/10.1371/journal.pone.0020005
14. Seubert A, Calabro S, Santini L, Galli B, Genovese A, Va len t i n i S, et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc Natl Acad Sci U S A 2011; 108: 11169-74; PMID: 21690334; http://dx.doi.org/10.1073/pn a s.11079 4110 8
15. Wilkinson TM, Li CKF, Chui CSC, Huang AKY, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18: 274-80; PMID: 22286307; http://dx.doi.org/10.1038/nm.2612
16. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, et al.; Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59(RR-8): 1-62; PMID: 20689501
17. Kelso A. CD4+ T cells limit the damage in influenza. Nat Med 2012; 18: 200-2; PMID: 22310682; http://dx.doi.org/10.1038/nm.2654
18. World Health Organization. Japanese encephalitis vaccines. Wkly Epidemiol Rec 2006; 81: 331-40; PMID: 16933380
19. Chen YJ, Hsu FK, Hsu LC. Current development and use of Japanese encephalitis vaccine. Taiwan Epidemiol Bull. 2013; 29: 129-41
20. Pan SC, Kung HC, Kao TM, Wu H, Dong SX, Hu MH, et al. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan. J Microbiol Immunol Infect 2012; S1684-1182; PMID: 23022464
21. Chong P, Hsieh SY, Liu CC, Chou AH, Yuan CJ, et al. Production of EV71 vaccine candidates. Hum Vaccin Immunother 2012; 8: 1-9 PMID: 22992566;; http://dx.doi.org/10.4161/hv.21739
22. Chou AH, Liu CC, Chang CP, Guo MS, Hsieh SY, Yang WH, et al. Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates. PLoS One 2012; 7:e34834; PMID: 22529942; http://dx.doi.org/10.1371/journal.pone. 0034834
23. Chang CY, Lin CW, Chiang CK, Chen PL, Huang CY, et al. Enzymatic stability and immunoregulatory efficacy of a synthetic indolicidin analogue with regular enantiomeric sequence. ACS Med Chem Lett. 2013; 4: 522-6; http://dx.doi.org/10.1021/ml400081f